Parkinson's disease is a progressive neurodegenerative movement disorder characterized by bradykinesia, rigidity, tremor, and non-motor symptoms due to dopaminergic neuronal loss.
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
Researchers have developed an integrated live-cell imaging and cytometry workflow to monitor brain organoid differentiation. Separately, experiments on the International Space Station show that microgravity accelerates organoid aging by roughly a decade in 30 days, offering a faster model for neurodegenerative diseases. These advances could enhance drug discovery and neurodevelopmental research.
Two experimental ALS therapies showed promise in recent clinical developments. Interim Phase 1/2 data suggest the antisense oligonucleotide QRL-201 restores a critical nerve protein and may slow disease decline, with a Phase 3 trial planned for 2027. Meanwhile, the oral therapy neflamapimod has been selected for testing in the UK's EXPERTS-ALS platform study, with first results expected this spring.
Studies found gut microbiome changes linked to Parkinson’s risk before symptoms and hair mineral differences in diagnosed patients. Both findings need larger follow-up studies.
UC San Diego is using space-based research to fight cancer and Alzheimer's, including the longest-running biologic experiments in space. A 2024 World Economic Forum report forecasts the space economy reaching $1.8 trillion by 2035.
Two studies identify protein recycling dysfunction and transcription factors ZSCAN20/JDP2 as drivers of T-cell exhaustion, with E3 ligases and gene deactivation offering reversal pathways. A third study finds TCF1 insufficient to revert terminally exhausted T cells.
AbbVie posted record full-year 2025 revenue of $61.2B and raised its 2026 outlook after strong Q1 Skyrizi and Rinvoq sales. Phase 3 AFFIRM data and new FDA submissions highlight pipeline progress, while full-year revenue guidance was lifted to $67.3B.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
New market research reports analyze biotechnology collaboration agreements from 2020-2026, gas chromatography market growth projections, and Western blotting market trends through 2035.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06036433 |
Light Therapy Plus Exercise to Improve Motor, Non-Motor Symptoms and QoL in Parkinson's Disease |
UNKNOWN | NA |
| NCT05518617 |
Molecular and Functional Imaging in Monogenic PD. |
RECRUITING | |
| NCT05516732 |
Serotonin Release in Premotor and Motor PD |
RECRUITING | |
| NCT05516719 |
Longitudinal Investigation of I2BS in PD |
RECRUITING | |
| NCT02670161 |
Quality Improvement and Practice Based Research in Neurology Using the EMR |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT02561715 |
Lack of Awareness of Symptoms (Anosognosia) in PD: An Observational Study for People With Parkinson's |
WITHDRAWN | |
| NCT02468804 |
Cognitive Dysfunction In Parkinson's |
COMPLETED | NA |
| NCT02315781 |
tDCS in Parkinson's Disease With Depression |
TERMINATED | NA |
| NCT02271685 |
Sound Estimation and Accuracy Task |
COMPLETED | NA |
| NCT02177149 |
Nurse Management of Neuromodulation Therapy |
WITHDRAWN | NA |
